3 ms·

Brazzy is right and you are wrong. For big pharma to extort, first they need the product that actually works. Most gene therapy is pipe dream. There are some d

by NoPie 5y ago

Brazzy is right and you are wrong. For big pharma to extort, first they need the product that actually works. Most gene therapy is pipe dream. There are some drugs on the market for some orphan (rare) diseases but the development is very costly and the market is very small. Obviously it will mean that the price will be very high. Most people are not in the position to pay it and it is up to the insurers or the government to decide if they can afford it or not. Here is the story of the first approved gene therapy drug: https://en.wikipedia.org/wiki/Alipogene_tiparvovec https://en.wikipedia.org/wiki/Alipogene_tiparvovec They sold the drug to 1 person only. The original company developing this drug went bankrupt.

giantg2 5y ago
That's a pretty bold claim to blanketly say that one person is wrong and another is right when there are multiple points in each statement. Do you realize they went bankrupt largely due to their pricing model? If you have a valid market and plan, you can get funding. This seems like they didn't have a good plan. Just because you give one example of a bankrupt small company doesn't mean that is representative of the industry. There are plenty of examples of other companies being successful. Some of these tend to get bought out by the larger companies. This article suggests that R&D costs about $1M (and 2 people recieved the treatment from the company that went bankrupt due to the high price). I'm sure there are additional costs for testing and approval. https://geneticliteracyproject.org/2017/12/12/gene-therapy-challenge-how-much-cost-pay/ https://geneticliteracyproject.org/2017/12/12/gene-therapy-c... Having executives making a combined $14M per year seems like a major factor in the price when the patient population is small. For example, 1k patients per year would have to pay $140k each just to cover the executive overhead. https://www.execpay.org/company/jeffrey-d-marrazzo-766 https://www.execpay.org/company/jeffrey-d-marrazzo-766

by NoPie 5y ago

giantg2 5y ago

That's a pretty bold claim to blanketly say that one person is wrong and another is right when there are multiple points in each statement. Do you realize they went bankrupt largely due to their pricing model? If you have a valid market and plan, you can get funding. This seems like they didn't have a good plan. Just because you give one example of a bankrupt small company doesn't mean that is representative of the industry. There are plenty of examples of other companies being successful. Some of these tend to get bought out by the larger companies. This article suggests that R&D costs about $1M (and 2 people recieved the treatment from the company that went bankrupt due to the high price). I'm sure there are additional costs for testing and approval. https://geneticliteracyproject.org/2017/12/12/gene-therapy-challenge-how-much-cost-pay/ https://geneticliteracyproject.org/2017/12/12/gene-therapy-c... Having executives making a combined $14M per year seems like a major factor in the price when the patient population is small. For example, 1k patients per year would have to pay $140k each just to cover the executive overhead. https://www.execpay.org/company/jeffrey-d-marrazzo-766 https://www.execpay.org/company/jeffrey-d-marrazzo-766